User contributions for Rithish Nimmagadda
Jump to navigation
Jump to search
11 May 2024
- 22:3822:38, 11 May 2024 diff hist 0 User:Rithish Nimmagadda →Pages Authored/Co-authored/Collaborated current
- 22:3422:34, 11 May 2024 diff hist +22 User:Rithish Nimmagadda →Pages Authored/Co-authored/Collaborated
- 22:3222:32, 11 May 2024 diff hist +13 Mirikizumab-mrkz No edit summary current
- 22:3122:31, 11 May 2024 diff hist 0 Mirikizumab-mrkz No edit summary
- 22:2622:26, 11 May 2024 diff hist +5,235 Mirikizumab-mrkz No edit summary
- 20:4820:48, 11 May 2024 diff hist −2 User:Rithish Nimmagadda →Pages Authored/Co-authored/Collaborated
- 20:4820:48, 11 May 2024 diff hist +16 User:Rithish Nimmagadda →Pages Authored/Co-authored/Collaborated
- 20:2120:21, 11 May 2024 diff hist +3,351 N Elfabrio Created page with "{{DrugProjectFormSinglePage |authorTag={{VSRN}} |genericName=Pegunigalsidase Alfa-iwxj |drugClass=a hydrolytic lysosomal neutral glycosphingolipid-specific enzyme, is a pegylated recombinant form of human α-galactosidase A |indicationType=treatment |indication=ELFABRIO is an FDA approved drug that is used for treatment of adults with confirmed Fabry disease. |hasBlackBoxWarning=Yes |adverseReactions=Most common adverse reactions (≥15%) are infusion-associated reactio..." current
- 19:3619:36, 11 May 2024 diff hist +44 N Exxua Created page with "{{DrugProjectFormSinglePage |authorTag={{ }}" current
9 May 2024
- 14:3514:35, 9 May 2024 diff hist +123 User:Rithish Nimmagadda →Education
- 14:3214:32, 9 May 2024 diff hist +11,409 Epcoritamab-bysp No edit summary current
- 13:1413:14, 9 May 2024 diff hist +4 Epcoritamab-bysp No edit summary
- 13:1013:10, 9 May 2024 diff hist +46 N Epcoritamab-bysp Created page with "{{DrugProjectFormSinglePage |authorTag=VSRN }}"
8 May 2024
- 14:4414:44, 8 May 2024 diff hist +81 N Template:VSRN Created page with "Rithish Nimmagadda,MBBS.[mailto:rithishnvs@gmail.com]" current
- 14:3014:30, 8 May 2024 diff hist +2 FRUZAQLA No edit summary current Tag: Visual edit
- 14:2514:25, 8 May 2024 diff hist +35 FRUZAQLA No edit summary
- 14:2114:21, 8 May 2024 diff hist −9 User:Rithish Nimmagadda →Your Name
- 14:2114:21, 8 May 2024 diff hist +9 User:Rithish Nimmagadda →Your Name
- 14:2014:20, 8 May 2024 diff hist +362 N User:Rithish Nimmagadda Created page with "<nowiki> __NOTOC__ ==Your Name== ''' Rithish Nimmagadda, MBBS Research scholar <br />Contact:945-278-1660 <br /> Email: rithishnvs@gmail.com [mailto:rithishnvs@gmail.com]<br /> ==Current Position== * research scholar (list chapters here)<br /> ==Education== Medical Degree from Kamineni Academy of Medical sciences and research centre , Hyderabad , India"
- 14:1014:10, 8 May 2024 diff hist +9,092 N FRUZAQLA Created page with "{{DrugProjectFormSinglePage |aOrAn=a |indicationType=treatment |indication=FRUZAQLA is a kinase inhibitor indicated for the treatment of adult patients with metastatic colorectal cancer (mCRC) who have been previously treated with fluoropyrimidine‑, oxaliplatin‑, and irinotecan‑based chemotherapy, an anti‑VEGF therapy, and, if RAS wild‑type and medically appropriate, an anti-EGFR therapy. |adverseReactions=Most common adverse reactions ( are hypertension, palma..."
- 13:3213:32, 8 May 2024 diff hist +49 N Fruzaqla Created page with "{{DrugProjectFormSinglePage |authorTag=rithish }}" current